2008
DOI: 10.1177/107327480801504s03
|View full text |Cite
|
Sign up to set email alerts
|

Changing the Treatment Paradigm in Myelodysplastic Syndromes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
12
0

Year Published

2010
2010
2014
2014

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 17 publications
(12 citation statements)
references
References 54 publications
0
12
0
Order By: Relevance
“…Secondly the dose of alemtuzumab used might be too high for high risk AML and MDS patients. Although the British experience with alemtuzumab‐based regimens in MDS was favourable (Mufti & Chen, 2008), the use of radioimmunotherapy might aggravate the immunosuppressive state for a longer period of time and might additionally suppress the activation of allogeneic effector cells. We therefore decided to amend the current protocol and reduce the dose of alemtuzumab to 50 mg. Of course, one has to be aware that strategies harnessing GvL reactions might put several of these older patients at an increased risk for life‐threatening acute and chronic GvHD.…”
Section: Discussionmentioning
confidence: 99%
“…Secondly the dose of alemtuzumab used might be too high for high risk AML and MDS patients. Although the British experience with alemtuzumab‐based regimens in MDS was favourable (Mufti & Chen, 2008), the use of radioimmunotherapy might aggravate the immunosuppressive state for a longer period of time and might additionally suppress the activation of allogeneic effector cells. We therefore decided to amend the current protocol and reduce the dose of alemtuzumab to 50 mg. Of course, one has to be aware that strategies harnessing GvL reactions might put several of these older patients at an increased risk for life‐threatening acute and chronic GvHD.…”
Section: Discussionmentioning
confidence: 99%
“…Until some years ago, active treatment options for patients with high-risk MDS were limited to hematopoietic stem cell transplantation (HSCT) and chemotherapy. While HSCT remains the only potentially curative treatment in eligible candidates, it is rarely applicable to the majority (mainly due to advanced age and/or comorbidities) [6], and chemotherapy has shown limited efficacy [7,8] and should be reserved for patients with a normal karyotype. However, alternative nonaggressive treatment options that can improve outcomes in a broader range of patients are now available or are under development.…”
Section: Introductionmentioning
confidence: 99%
“…More recently, alemtuzumab has also been administered in patients with MDS (30,31). The primary rational of this approach has been the observation that T-celltargeting immunosuppressive agents, like anti-thymocyte globulin, are effective in a subgroup of patients, especially those with hypoplastic MDS (32,33). Alemtuzumab was also found to induce remarkable responses and even remission in a few patients with MDS (30,31).…”
Section: Introductionmentioning
confidence: 99%